NewslettersMesenchymal Cell Newsāshibio Doses First Patient in ANDECAL Study, a Phase II/III Trial of Andecaliximab for Treatment of Fibrodysplasia Ossificans Progressiva (FOP)By Emily Salmini - January 28, 2025020āshibio announced the dosing of the first participant in its ANDECAL study, a Phase II/III clinical trial evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of andecaliximab in patients with FOP.[āshibio]Press Release